MACRO trial researchers said adapting to the COVID-19 pandemic mid-trial may have undercut the efficacy of the intervention, ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Marc P. Bonaca, MD, MPH, is the executive director of CPC Clinical Research, the director of Vascular Research, a professor in the Division of Cardiology at the University of Colorado School of ...

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...

Despite showing no overall benefit, the in-home paramedic visit appeared to help women avoid readmissions more than men.

Geoffrey Rutledge, MD, PhD, of HealthTap, envisions a future where all patients have a virtual care doctor as their first point of contact with the health care system.

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Implementing artificial intelligence (AI) has transformed clinicians' and health systems' ability to screen for and distinguish forms of cardiorenalmetabolic disease.

Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an ...

Although the widespread adoption of remote patient monitoring during the COVID-19 pandemic expanded care access, particularly for underserved communities, challenges persist in sustaining this access.